Compare KLXE & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KLXE | EVAX |
|---|---|---|
| Founded | 2018 | 2008 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.8M | 31.9M |
| IPO Year | 2018 | 2020 |
| Metric | KLXE | EVAX |
|---|---|---|
| Price | $2.30 | $4.14 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $11.67 |
| AVG Volume (30 Days) | ★ 267.4K | 21.9K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $636,600,000.00 | N/A |
| Revenue This Year | $3.89 | N/A |
| Revenue Next Year | $4.95 | $328.20 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.46 | $1.25 |
| 52 Week High | $3.45 | $12.15 |
| Indicator | KLXE | EVAX |
|---|---|---|
| Relative Strength Index (RSI) | 43.01 | 59.38 |
| Support Level | $2.14 | $3.32 |
| Resistance Level | $3.07 | $4.64 |
| Average True Range (ATR) | 0.26 | 0.30 |
| MACD | -0.06 | 0.03 |
| Stochastic Oscillator | 18.39 | 69.17 |
KLX Energy Services Holdings Inc is a provider of completion, intervention and production services and products to the onshore oil and gas producing regions of the United States. It serves the companies engaged in the exploration and development of onshore conventional and unconventional oil and natural gas reserves. Its products and services offerings include surface facilities and equipment, pressure control services, wireline services, fishing services, and engineered products. The company's segments include Southwest; Rocky Mountains and Northeast/Mid-Con region. It derives maximum revenue from Northeast/Mid-Con region.
Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options.